Skip to main content
Neovacs logo

Neovacs — Investor Relations & Filings

Ticker · ALNEV ISIN · FR001400MV37 LEI · 9695001J9GMM5XYK6482 Euronext Growth Professional, scientific and technical activities
Open in API
Filings indexed 453 across all filing types
Latest filing 2026-05-05 Regulatory Filings
Country FR France
Listing Euronext Growth ALNEV

About Neovacs

https://www.neovacs.com/en/

Neovacs is a biotechnology company with two main activities: research and development, and investment. The company's R&D focuses on its proprietary Kinoid technology platform, an active immunotherapy approach for treating autoimmune diseases and allergies. This technology develops therapeutic vaccines designed to stimulate the patient's immune system to regulate the overproduction of harmful cytokines. Key indications for its Kinoid products include lupus. In addition to its internal development, Neovacs invests in high-potential BioTech and MedTech companies, leveraging its experienced team to evaluate and support innovative products and medical devices.

Recent filings

Filing Released Lang Actions
L'agence nationale de la recherche (ANR) met en lumière le programme ARNm IgE 'AllergyVacs2' à l'occasion de la semaine Européenne de la vaccination.
Regulatory Filings
2026-05-05 French
Résultats annuels 2025
Regulatory Filings
2026-04-30 French
Le projet VECT-PI sélectionné pour un financement dans le cadre de France 2030
Capital/Financing Update Classification · 1% confidence The document is a press release by Neovacs announcing that its VECT-PI project has been officially selected for a €2 million funding grant under the France 2030 program. It discusses financing arrangements and grant funding rather than publishing financial results, regulatory filings, or corporate governance changes. This is an update on the company’s financing activity (receipt of grant funding), which fits the Capital/Financing Update category.
2026-04-29 French
Information relative au nombre total de droits de vote et d'actions composant le capital social
Share Issue/Capital Change Classification · 1% confidence The document is a press release by the company disclosing the total number of shares and voting rights composing its share capital, as well as monthly issuances from convertible securities (OCEANE, ORA/OS, BSAE). It is not a financial report, call transcript, or AGM materials, but rather an announcement of changes in share capital. This falls under “Share Issue/Capital Change” (SHA).
2026-04-15 French
Levée de fonds de 250 000 EUR
Capital/Financing Update Classification · 1% confidence The document is a press release titled “Levée de fonds de 250 000 €” announcing a new financing round via issuance of OCEANE-BSA convertible bonds and warrants, detailing amounts raised, dilution impact, and use of proceeds. It clearly describes a capital/financing update rather than a regulatory filing, earnings release, or share buyback. This matches the Capital/Financing Update category.
2026-03-25 French
Néovacs réduit fortement ses coûts et assure de la visibilité sur son plan de financement
Capital/Financing Update Classification · 1% confidence The document is a press release titled “COMMUNIQUÉ DE PRESSE” issued by Néovacs. It focuses entirely on the execution of a cost‐reduction plan and, more importantly, on the detailed implementation of a scheduled financing plan (monthly drawings of OCEANE‐BSA instruments, refinancing of assets, available credit line, etc.). There are no quarterly or annual financial results, no AGM materials, no share issue notification separate from a financing update, and no legal or corporate governance changes. The main purpose is to update investors on the company’s capital and financing structure and planned funding schedule. This clearly falls under Capital/Financing Update (CAP).
2026-03-24 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.